Statement Of Cash Flows [Abstract]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
3,166,000,000 SEK
3,093,000,000 SEK
Adjustments for increase (decrease) in trade and other payables
752,000,000 SEK
538,000,000 SEK
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
- SEK
0 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from sale or issue of treasury shares
15,000,000 SEK
- SEK
Payments for share issue costs
188,000,000 SEK
263,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.